论文部分内容阅读
目的探讨比伐卢定对高危急性冠脉综合征病人经皮冠状动脉介入治疗(PCI)术中抗凝血作用、临床疗效及安全性。方法选取我院心内科诊断为急性冠脉综合征病人68例,按随机数字表法分组,对照组34例术中应用普通肝素进行抗凝治疗,研究组34例术中应用比伐卢定进行抗凝治疗,比较两组凝血指标、临床疗效及不良反应状况。结果研究组不良事件发生率为2.94%,低于对照组的23.52%,差异有统计学意义(P<0.05);研究组总出血率为2.94%,低于对照组的20.59%,差异有统计学意义(P<0.05);与对照组比较,研究组用药后纤维蛋白原水平低于对照组,活化部分凝血活酶时间(APTT)、凝血酶原时间及凝血酶时间水平高于对照组,差异有统计学意义(P<0.05);与对照组比较,研究组病人术后1 h APTT值较高,术后4 h研究组病人APTT值较高,具有统计学意义(P<0.05)。结论比伐卢定在高危急性冠脉综合征病人PCI术中抗凝血效果显著,且不良反应较少。
Objective To investigate the anticoagulant effect, clinical efficacy and safety of bivalirudin in patients with high-risk acute coronary syndrome undergoing percutaneous coronary intervention (PCI). Methods Sixty-eight patients diagnosed with acute coronary syndrome in our hospital were selected according to the random number table method. 34 patients in the control group received unfractionated heparin for anticoagulation. 34 patients in the study group were treated with bivalirudin Anticoagulant therapy was used to compare the coagulation indexes, clinical efficacy and adverse reactions in the two groups. Results The incidence of adverse events was 2.94% in the study group, which was lower than 23.52% in the control group (P <0.05). The total bleeding rate in the study group was 2.94%, which was lower than that in the control group (20.59%) (P <0.05). Compared with the control group, the fibrinogen level of the study group was lower than that of the control group. The activated partial thromboplastin time (APTT), prothrombin time and thrombin time were higher than the control group, (P <0.05). Compared with the control group, APTT value of the study group was higher at 1 h after operation and APTT value was higher at 4 h after operation in the study group, with statistical significance (P <0.05). Conclusion Bivalirudin has a significant anticoagulant effect in patients with high-risk acute coronary syndromes and has fewer adverse reactions.